Shire agrees to supply Adderall XR generic to Sandoz

LONDON (Reuters) - Pharmaceutical company Shire said on Monday it had agreed to supply an authorized generic version of Adderall XR, its drug to treat hyperactivity, to Sandoz.

Adderall, an amphetamine, is available in instant release and extended release formulations. Shire now only produces the extended version, for which it retains patent rights, and sales of the drug have been falling since a generic version became available in 2009.

However, the drug still generated sales of $81.4 million for Shire in the third quarter of the year.

Under the agreement, Sandoz, the generic arm of Novartis, will exclusively sell the authorized generic version of Adderall XR supplied by Shire from July 1, 2016 in the United States, Shire said, adding it would receive a royalty on sales.

(Reporting by Paul Sandle; editing by Kate Holton)

View the original article here

India's Sun Pharma gets FDA nod for Prevacid generic drug

MUMBAI (Reuters) - India's Sun Pharmaceutical Industries Ltd said its unit has received U.S. Food and Drug Administration's (USFDA) final approval for the generic version of Prevacid.

The approval is for Lansoprazole Delayed-Release Capsules USP, 15 and 30 mg, which are therapeutic equivalents of Takeda Pharmaceutical Co. Ltd's capsules, the company said in a release late on Saturday.

The capsules have annual sales of $430 million in the United Sates, it said.

The capsules are used for short-term treatment for healing and symptom relief of active duodenal ulcer, it said.

(Reporting by Subhadip Sircar; Editing by Robert Birsel)

View the original article here